Peptides DB
Research-centric peptide and protocol reference hub

Follistatin-344 record · updated 17h ago

Muscle & body compHealing & recoveryGrade A · human clinicalResearch use only
All 16 studiesJump to the evidenceCompare
What is Follistatin-344 used for?

Follistatin-344 is a glycoprotein that plays a significant role in muscle growth and development by acting as an inhibitor of myostatin, a protein that negatively regulates muscle mass. By binding to myostatin and preventing its action, follistatin-344 promotes muscle hypertrophy and has garnered interest for its potential therapeutic applications in muscle wasting disorders, regenerative medicine, and other conditions related to muscle atrophy.

How it works: Myostatin inhibitor

Primarily researched for · Muscle & body comp

Development stage

where Follistatin-344 sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 44 registered trials. It describes the research record, not a recommendation.

Identity
NameFollistatin-344
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMuscle
Research levelWell Studied
Discovered byAdded before provenance tracking · 2025
Pharmacology
MechanismMyostatin inhibitor
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 24, 2026. How this works →
Research stats
Total studies16
Human / animal / cellular8 / 3 / 1
Highest trial phasePhase 4
Years covered2010–2026
Latest study8d ago
Publication history
20102026
Research funding
3,087 NIH projects · $23.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

16 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Effects of Different Training Modalities on Circulating Irisin Levels in Overweight and Obesity Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
FindingSMD 0.62, 95% CI 0.39-0.85, p < 0.001, n=76 arms, 1721 subjects for circulating irisin increase.
review2025Full text read0.90
Placental transcriptome analysis reveals BMI-dependent gene expression profiles in preeclampsia.
FindingSERPINA3 demonstrated an estimated eight-fold increase (95% CI: 3.9-16.6) in preeclamptic pregnancies complicated by obesity.
Human2026Full text read0.80
Serum-Free Expanded Hair Follicle Mesenchymal Stem Cells Promote Cartilage Repair in a Murine Full-Thickness Defect Model.
FindingSignificant improvement in histological cartilage repair scores relative to phosphate-buffered saline controls.
Animal2026Full text read0.80
Erratum for the Research Article "Follistatin gene delivery enhances muscle growth and strength in nonhuman primates".
TakeawayNot reported in abstract.
Animal2026Title only0.10
Intrafollicular activin-A, inhibin-B, and follistatin are associated with in vitro fertilization outcomes in subfertile women.
FindingEach 10 pg/mg increase in protein-normalized FF activin-A was associated with clinical pregnancy [RR (95% CI) = 0.76 (0.66-0.86), p<0.001].
Human2023Full text read0.80
Multimodal characterization of sustained bioagent release from an epicardial depot for long-term biomaterial incorporation.
FindingNot reported in abstract.
Animal2026Full text read0.70
Biophysical and computational characterization identifies FSTL1 as a novel binding target of doxorubicin.
FindingSNR = 5.763
In vitro2026Full text read0.70
Combined resistance exercise and essential amino acid intake enhance follistatin/myostatin ratio and muscle fitness in older women: a randomized controlled trial.
FindingF(3, 72) = 5.556, p = 0.002, partial η² = 0.188 for follistatin/myostatin ratio increase in RE + EAA group.
Human2026Full text read0.80
Effects of low-load resistance training with blood flow restriction and swallowing training on sarcopenic dysphagia in community-dwelling older people in China: a randomised controlled trial protocol.
FindingNot reported in abstract.
Human2026Partial text0.50
Intramuscular fat content and the risk of peritonitis in peritoneal dialysis patients.
FindingAdjusted hazard ratio for peritonitis-free survival 1.084, 95% CI 1.027 to 1.144, P = .004.
Human2026Full text read0.80
Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study
Finding28.9% reported full recovery at one year, n=804.
Human2021Full text read0.80
Longitudinal plasma proteomics along a menstrual cycle highlights the regulatory effect of sex hormones on inflammatory and cardiometabolic circuits.
FindingNot reported in abstract.
Human2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Follistatin-344 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Follistatin-344 is discussed should be drawn from it.